AT7867 dihydrochloride

Research use only, not for human use.

AT7867 is a potent, ATP-competitive, orally available dual Akt and p70S6K inhibitor with Ki of 17-85 nM.

AT7867 is a potent, ATP-competitive, orally available dual Akt and p70S6K inhibitor with Ki of 17-85 nM, also inhibits PKA with Ki of 20 nM; potently inhibits both AKT and p70S6K activity at the cellular level, as measured by inhibition of GSK3beta (IC50=7.1 uM, pSer9 GSK3β in U87MG glioblastoma cells) and S6 ribosomal protein phosphorylation, causes growth inhibition in a range of human cancer cell lines; inhibits AKT and p70S6K and induces apoptosis, inhibits human tumor growth in PTEN-deficient xenograft models.

AT-7867 dihydrochloride;AT 7867 dihydrochloride

Cytoskeleton/Cell Adhesion Molecules

Akt

Akt

Cancer

——

1431697-86-7

410.77

C20H22Cl3N3

>98% (HPLC)

10 mM in DMSO

ClC1=CC=C(C2(C3=CC=C(C4=CNN=C4)C=C3)CCNCC2)C=C1.[H]Cl.[H]Cl

Piperidine, 4-(4-chlorophenyl)-4-[4-(1H-pyrazol-4-yl)phenyl]-, hydrochloride (1:2)

(-20℃)

With Ice Pack

≥ 2 years